Clinical and prognostic implications of β1, 6-N-acetylglucosaminyltransferase V in patients with gastric cancer

Cancer Science

Volumn 104, Issue 2, 2013, Pages 185-193

  Wang, Xuefei ^a   He, Hongyong ^a   Zhang, Heng ^a   Chen, Weidong ^a   Ji, Yuan ^b   Tang, Zhaoqing ^a   Fang, Yong ^a   Wang, Cong ^a   Liu, Fenglin ^a   Shen, Zhenbin ^a   Qin, Jing ^a   Zhu, Yu ^b   Liu, Haiou ^b   Xu, Jiejie ^b   Gu, Jianxin ^b   Qin, Xinyu ^a   Sun, Yihong ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1, 6 N ACETYLGLUCOSAMINYLTRANSFERASE 5; N ACETYLGLUCOSAMINYLTRANSFERASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER STAGING; CELL DIFFERENTIATION; CHINA; CLINICAL FEATURE; CYTOPLASM; DISTANT METASTASIS; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PARTIAL GASTRECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH EPITHELIUM; STROMA CELL; TUMOR DIFFERENTIATION; TUMOR VOLUME;

ADENOCARCINOMA; AGED; CELL DIFFERENTIATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; N-ACETYLGLUCOSAMINYLTRANSFERASES; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; RISK; STOMACH NEOPLASMS;

EID: 84873714353     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12049     Document Type: Article

References (27)

1. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet 2009; 374: 477-90.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
3. Washington K. 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol 2010; 17: 3077-9.
4. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 2011; 14: 113-23.
5. Warneke VS, Behrens HM, Hartmann JT et al. Cohort study based on the seventh edition of the TNM classification for gastric cancer: proposal of a new staging system. J Clin Oncol 2011; 29: 2364-71.
6. Lim L, Michael M, Mann GB, Leong T. Adjuvant therapy in gastric cancer. J Clin Oncol 2005; 23: 6220-32.
7. Raman R, Raguram S, Venkataraman G, Paulson JC, Sasisekharan R. Glycomics: an integrated systems approach to structure-function relationships of glycans. Nat Methods 2005; 2: 817-24.
8. Dube DH, Bertozzi CR. Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nat Rev Drug Discov 2005; 4: 477-88.
9. Fernandes B, Sagman U, Auger M, Demetrio M, Dennis JW. Beta 1-6 branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia. Cancer Res 1991; 51: 718-23.
10. Seelentag WK, Li WP, Schmitz SF et al. Prognostic value of beta1, 6-branched oligosaccharides in human colorectal carcinoma. Cancer Res 1998; 58: 5559-64.
11. Murata K, Miyoshi E, Kameyama M et al. Expression of N-acetylglucosaminyltransferase V in colorectal cancer correlates with metastasis and poor prognosis. Clin Cancer Res 2000; 6: 1772-7.
12. Granovsky M, Fata J, Pawling J, Muller WJ, Khokha R, Dennis JW. Suppression of tumor growth and metastasis in Mgat5-deficient mice. Nat Med 2000; 6: 306-12.
13. Dosaka-Akita H, Miyoshi E, Suzuki O, Itoh T, Katoh H, Taniguchi N. Expression of N-acetylglucosaminyltransferase V is associated with prognosis and histology in non-small cell lung cancers. Clin Cancer Res 2004; 10: 1773-9.
14. Ishimura H, Takahashi T, Nakagawa H et al. N-acetylglucosaminyltransferase V and beta1-6 branching N-linked oligosaccharides are associated with good prognosis of patients with bladder cancer. Clin Cancer Res 2006; 12: 2506-11.
15. Zhu XD, Zhang JB, Zhuang PY et al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol 2008; 26: 2707-16.
16. Weichert W, Roske A, Gekeler V et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 2008; 9: 139-48.
17. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005; 23: 9067-72.
18. Bang YJ, van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-97.
19. Dennis JW, Granovsky M, Warren CE. Glycoprotein glycosylation and cancer progression. Biochim Biophys Acta 1999; 1473: 21-34.
20. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2004; 4: 45-60.
21. Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 2005; 5: 526-42.
22. Tian H, Miyoshi E, Kawaguchi N et al. The implication of N-acetylglucosaminyltransferase V expression in gastric cancer. Pathobiology 2008; 75: 288-94.
23. Perng GS, Shoreibah M, Margitich I, Pierce M, Fregien N. Expression of N-acetylglucosaminyltransferase V mRNA in mammalian tissues and cell lines. Glycobiology 1994; 4: 867-71.
24. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011; 14: 101-12.
25. Bang YJ, Kim YW, Yang HK et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012; 379: 315-21.
26. Lee J, Lim do H, Kim S et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 2012; 30: 268-73.
27. Yoshikawa T, Sasako M. Gastrointestinal cancer: adjuvant chemotherapy after D2 gastrectomy for gastric cancer. Nat Rev Clin Oncol 2012; 9: 192-4.